The Trump administration is closing a loophole that drugmakers could use to avoid negotiations when they add active ...
If you’re considering taking a GLP-1 (glucagon-like peptide-1) receptor agonist for weight loss, here’s what to know about the long-term benefits and risks, along with insights from physicians. GLP-1 ...
Zacks Investment Research on MSN
Can Medicare Bridge help Novo Nordisk defend its GLP-1 leadership?
Novo Nordisk NVO has received another commercial boost as the Medicare GLP-1 Bridge program officially went live on July 1, ...
The Hearty Soul on MSN
New diabetes treatment may replace insulin injections with sweet treat
A new oral insulin embedded in sugar-free chocolate uses nano-carriers to target the liver, cutting hypoglycemia risk. The ...
Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright ...
SEC asks Abbvie to conduct Phase III study on subcutaneous drug for Parkinson's disease: Our Bureau, New Delhi Friday, July 3, 2026, 08:00 Hrs [IST] A Subject Expert Committee (SE ...
Tennessee's lethal injection protocol adopted a year and a half ago appears to include reduced training in IV placement. That ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results